These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29558894)

  • 21. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making.
    Tu HAT; de Vries R; Woerdenbag HJ; Li SC; Le HH; van Hulst M; Postma MJ
    Value Health Reg Issues; 2012 May; 1(1):7-14. PubMed ID: 29702830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluations of hepatitis B vaccination for developing countries.
    Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
    Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
    Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
    Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.
    Kim SY; Salomon JA; Goldie SJ
    Bull World Health Organ; 2007 Nov; 85(11):833-42. PubMed ID: 18038073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).
    La Torre G; Mannocci A; Saulle R; Colamesta V; Meggiolaro A; Mipatrini D; Sinopoli A
    Hum Vaccin Immunother; 2016 Sep; 12(9):2299-311. PubMed ID: 27105443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
    PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems.
    Main C; Moxham T; Wyatt JC; Kay J; Anderson R; Stein K
    Health Technol Assess; 2010 Oct; 14(48):1-227. PubMed ID: 21034668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
    Coward S; Leggett L; Kaplan GG; Clement F
    BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY; Billah K; Lieu TA; Weinstein MC
    Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
    Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
    Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine prenatal screening of Indian women for HBsAg: benefits derived versus cost.
    Sriprakash I; Anil TP
    Trop Doct; 1997 Jul; 27(3):176-7. PubMed ID: 9227020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic analysis of adult hepatitis B vaccination in China.
    Zheng H; Wang FZ; Zhang GM; Cui FQ; Wu ZH; Miao N; Sun XJ; Liang XF; Li L
    Vaccine; 2015 Nov; 33(48):6831-9. PubMed ID: 26384449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review.
    Erfani P; Bhangdia K; Stauber C; Mugunga JC; Pace LE; Fadelu T
    Oncologist; 2021 Aug; 26(8):e1406-e1417. PubMed ID: 34050590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economics of physical activity in low-income and middle- income countries: a systematic review.
    Ranasinghe PD; Pokhrel S; Anokye NK
    BMJ Open; 2021 Jan; 11(1):e037784. PubMed ID: 33452186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
    Crespo J; Esteban R; Torres C; Oyagüez I; Casado MÁ; Buti M
    Rev Esp Enferm Dig; 2017 Sep; 109(9):619-626. PubMed ID: 28648087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.